Details of Disease

General Information of Disease (ID: DIS3QDT8)

Disease Name	Malignant uterine tumour
Synonyms	uterus neoplasm; uterine tumour; uterine tumor; tumour of uterus; tumor of uterus; neoplasm of uterus; uterus cancer; uterine cancer; malignant uterus neoplasm; malignant uterine tumour; malignant uterine tumor; malignant uterine neoplasm; malignant tumour of uterus; malignant tumour of the uterus; malignant tumor of uterus; malignant tumor of the uterus; malignant neoplasm of uterus; malignant neoplasm of the uterus; cancer of uterus; cancer of the uterus; CA - cancer of uterus
Disease Class	2C76: Endometrial cancer
Definition	Primary or metastatic malignant neoplasm involving the uterine corpus and/or the cervix.
Disease Hierarchy	DIST2NIJ: Gynecologic cancer DISAT1Z9: Advanced cancer DIS5Z2HI: Tumor of uterus DIS3QDT8: Malignant uterine tumour
ICD Code	ICD-11 ICD-11: 2C76.Z
Disease Identifiers	MONDO ID MONDO_0002715 MESH ID D014594 UMLS CUI C0153567 MedGen ID 57791 SNOMED CT ID 371973000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
XBIO-101	DMUI7WV	Phase 2	NA	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 8 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
BAP1	TT47RXJ	moderate	Biomarker	[2]
CDKN1B	TTLGFVW	Strong	Biomarker	[3]
CTCFL	TTY0RZT	Strong	Altered Expression	[4]
HMGA1	TTBA219	Strong	Biomarker	[5]
PROM1	TTXMZ81	Strong	Biomarker	[6]
SLC39A6	TTZN1CF	Strong	Altered Expression	[7]
INHBA	TTVB30D	Definitive	Biomarker	[8]
SMAD3	TTHQZV7	Definitive	Biomarker	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 DTT(s)

This Disease Is Related to 11 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FOXA2	OTJOCVOY	moderate	Biomarker	[9]
PPP2R1A	OTYA3GB4	moderate	Genetic Variation	[10]
ABCF2	OTXIBZ3N	Strong	Altered Expression	[11]
BARD1	OTTC0Z9Y	Strong	Genetic Variation	[12]
CCDC54	OTW5WCX9	Strong	Biomarker	[13]
CDC42SE2	OT8SG9I1	Strong	Biomarker	[14]
HOXB9	OTMVHQOU	Strong	Biomarker	[15]
MDH2	OT7364GY	Strong	Biomarker	[16]
RHOU	OTERIAD4	Strong	Altered Expression	[17]
RNF26	OTPXA60S	Strong	Altered Expression	[18]
SPA17	OT8J7T7U	Strong	Biomarker	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 DOT(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.Genes Chromosomes Cancer. 2015 Jan;54(1):51-62. doi: 10.1002/gcc.22218. Epub 2014 Sep 18.
3	A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression.Genes Dev. 2006 Jan 1;20(1):47-64. doi: 10.1101/gad.1384406.
4	Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression.Clin Cancer Res. 2007 Mar 15;13(6):1713-9. doi: 10.1158/1078-0432.CCR-05-2569.
5	The High Mobility Group A1 (HMGA1) gene is highly overexpressed in human uterine serous carcinomas and carcinosarcomas and drives Matrix Metalloproteinase-2 (MMP-2) in a subset of tumors.Gynecol Oncol. 2016 Jun;141(3):580-587. doi: 10.1016/j.ygyno.2016.03.020. Epub 2016 Apr 8.
6	CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mllerian tumor). Stem Cells. 2011 Oct;29(10):1485-95. doi: 10.1002/stem.711.
7	SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.
8	A high concentration of genistein down-regulates activin A, Smad3 and other TGF-beta pathway genes in human uterine leiomyoma cells. Exp Mol Med. 2012 Apr 30;44(4):281-92.
9	The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.
10	Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.Cancer Res. 2016 Oct 1;76(19):5719-5731. doi: 10.1158/0008-5472.CAN-15-3342. Epub 2016 Aug 2.
11	Can ABCF2 protein expression predict the prognosis of uterine cancer?.Br J Cancer. 2008 Nov 18;99(10):1651-5. doi: 10.1038/sj.bjc.6604734.
12	Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.Int J Cancer. 2006 Mar 1;118(5):1215-26. doi: 10.1002/ijc.21428.
13	In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer.Int J Mol Sci. 2016 Sep 9;17(9):1525. doi: 10.3390/ijms17091525.
14	Biologic effects of platelet-derived growth factor receptor blockade in uterine cancer.Clin Cancer Res. 2014 May 15;20(10):2740-50. doi: 10.1158/1078-0432.CCR-13-2507. Epub 2014 Mar 14.
15	Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo. Gene. 2016 Sep 30;590(2):234-43. doi: 10.1016/j.gene.2016.05.009. Epub 2016 May 13.
16	Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer.J Cell Mol Med. 2015 Apr;19(4):744-59. doi: 10.1111/jcmm.12388. Epub 2015 Jan 30.
17	Expression of WRCH1 in human cancer and down-regulation of WRCH1 by beta-estradiol in MCF-7 cells.Int J Oncol. 2002 Apr;20(4):777-83.
18	Molecular cloning and characterization of RNF26 on human chromosome 11q23 region, encoding a novel RING finger protein with leucine zipper.Biochem Biophys Res Commun. 2001 Apr 13;282(4):1038-44. doi: 10.1006/bbrc.2001.4671.